Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  ibritumomab tiuxetan
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-13 of 13 for your search:
Start Over
Phase III Randomized Study of IDEC-Y2B8 Radioimmunotherapy Versus Rituximab Immunotherapy for Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: IDEC-106-04, MAYO-977802
Phase III Study of IDEC-Y2B8 in Patients With Progressive Follicular B-Cell Non-Hodgkin's Lymphoma That is Refractory to Prior Rituximab Therapy
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: IDEC-106-06, MAYO-987804, UCLA-9808026
Study Comparing the Zevalin Regimen With no Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R
Phase: Phase III
Type: Treatment
Status: Closed
Age: 60 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 307940/106-20, NCT00322218
Phase II Study of Ibritumomab Tiuxetan (IDEC-Y2B8) Radioimmunotherapy in Patients with Relapsed or Refractory, Low Grade or B-Cell, Non-Hodgkin's Lymphoma and Mild Thrombocytopenia
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-9804024, IDEC-106-05, NCI-G99-1614
Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCI #03-005, NCT00177554
A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 59
Sponsor: Other
Protocol IDs: 2007.462, NCT00498043
Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 70
Sponsor: Other
Protocol IDs: GELTAMO-LCM-04-02, 2005-004400-37, NCT00505232
Zevalin(Ibritumomab Tiuxetan)+ Rituximab Maintenance
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: HO04405, NCT00582166
Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 65
Sponsor: Other
Protocol IDs: CHUBX 2007/11, NCT00607854
Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000067697, UAB-9930, IDEC-106-98, GUMC-00095, NCI-G00-1731, NCT00005592
Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Phase: Phase I
Type: Treatment
Status: Completed
Age: 65 and over
Sponsor: Other
Protocol IDs: SAKK 37/05, SWS-SAKK-37/05, EU-20648, SPRI-SWS-SAKK-37/05, CDR0000511915, NCT00392691
Start Over